Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study
Circulation · 2025
DOI: 10.1161/circulationaha.124.070865 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Circulation, 2025. Verfasst von Kavi Grewal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine (K.G.), University of Toronto, Canada. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Neoplasms, Hemorrhage. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Bleeding after starting anticoagulation for atrial fibrillation (AF) may be the first sign of malignancy, especially in elderly individuals. There are no recommendations to guide investigations for malignancy after new-onset bleeding after anticoagulation for AF. Our objective was to determine the association of bleeding after starting oral anticoagulation for AF with new diagnoses of malignancy in a population-wide sample. METHODS: We conducted a population-based cohort study using linked administrative data sets of people ≥66 years of age who newly initiated warfarin or direct oral anticoagulants after diagnosis with AF between 2008 and 2022. Follow-up was 2 years after starting anticoagulation. We excluded patients with valvular disease, chronic dialysis, venous thromboembolism, previous cancer, or previously documented bleeding. Bleeding was identified from hospital/emergency department discharge records and physician billings, then handled as a time-varying covariate in cause-specific regression models while adjusting for baseline characteristics. The primary outcome was incident malignancy. We also determined the site of origin of the malignancy and the stage at diagnosis if indicated in the Ontario Cancer Registry. Analyses were repeated while limiting the exposure to specific bleeding sites. RESULTS: Among 119 480 people (mean age, 77.4 years; 52% men) who started anticoagulants, 26 037 (21.8%) had documented bleeding, and 5800 (4.9%) were diagnosed with malignancy within the next 2 years. Bleeding was associated with a higher hazard of cancer diagnosis with a hazard ratio (HR) of 4.0 (95% CI, 3.8–4.3). The HRs for any malignancy were 5.0 (95% CI, 4.6–5.5) for gastrointestinal, 5.0 (95% CI, 4.4–5.7) for genitourinary, 4.0 (95% CI, 3.5–4.6) for respiratory, 1.8 (95% CI, 1.4–2.2) for intracranial, and 1.5 (95% CI, 1.2–2.0) for nasopharyngeal bleeds. The HRs were substantially higher for cancers concordant with the bleeding site (gastrointestinal, 15.4; genitourinary, 11.8; respiratory, 10.1). Cancers were diagnosed at an earlier stage after bleeding (27.6% stage 4 after bleeding versus 31.3% without bleeding; P =0.029). CONCLUSIONS: In anticoagulated patients with AF, bleeding was strongly associated with new cancer diagnoses. Antecedent bleeding was associated with cancer diagnosis at an earlier stage. This highlights the importance of timely investigations in patients with bleeding after anticoagulation for AF, rather than attributing bleeding as an expected adverse effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Temerty Faculty of Medicine (K.G.), University of Toronto, Canada.
- Department of Medicine, Women's College Hospital, Toronto, Canada (K.G., H.A.-Q.).
- ICES (formerly known as the Institute for Clinical Evaluative Sciences), Toronto, Canada (X.W., P.C.A., C.A.J., I.N.-A., D.T.K., D.S.L., H.A.-Q.).
- Institute of Health Policy, Management, and Evaluation (P.C.A., C.A.J., I.N.-A., D.S.L., H.A.-Q.), University of Toronto, Canada.
- Department of Pharmacy, Veterans Affairs Greater Los Angeles Healthcare System, CA (C.A.J.).
- Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA (C.A.J.).
ORCID-Profile: Peter C Austin, Cynthia A Jackevicius, Dennis T Ko, Douglas S Lee, Paaladinesh Thavendiranathan, Michael Fradley, Paul Dorian, Husam Abdel-Qadir
Zitieren
APA
Grewal, K., Wang, X., Austin, P. C., Jackevicius, C. A., Nardi-Agmon, I., Ko, D. T., Lee, D. S., Thavendiranathan, P., Fradley, M., Dorian, P., & Abdel-Qadir, H. (2025). Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study. Circulation. https://doi.org/10.1161/circulationaha.124.070865
Vancouver
Grewal K, Wang X, Austin PC, Jackevicius CA, Nardi-Agmon I, Ko DT, et al. Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study. Circulation. 2025. doi:10.1161/circulationaha.124.070865
BibTeX
@article{Grewal2025,
author = {Grewal, Kavi and Wang, Xuesong and Austin, Peter C and Jackevicius, Cynthia A and Nardi-Agmon, Inbar and Ko, Dennis T and Lee, Douglas S and Thavendiranathan, Paaladinesh and Fradley, Michael and Dorian, Paul and Abdel-Qadir, Husam},
title = {Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study},
journal = {Circulation},
year = {2025},
doi = {10.1161/circulationaha.124.070865}
}
EUVIMED